ClinicalTrials.gg
WithdrawnNCT02906605Updated Nov 22, 2016

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

A Phase 2 interventional study of JNJ-809 and Apalutamide in Prostatic Neoplasms, Castration-Resistant, sponsored by Janssen Research & Development, LLC. Withdrawn at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-22.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study start delayed due to pending collection and analysis of additional phase 1 data.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson — 3 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · Johnson & Johnson.

Enrollment
10th of 10
0 · median 77
Started
2016
with 1 other
Phase 2
2 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, this one is the 10th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 4th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

3 of the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with apalutamide is improved compared with apalutamide alone for subjects with metastatic castration-resistant prostate cancer (mCRPC).

03

Conditions studied

  • Prostatic Neoplasms, Castration-Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the prostate
  • disease as documented by technetium-99m (99mTc) bone scan or metastatic lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans
  • Surgically or medically castrated, with testosterone levels of less than (\<)50 nanogram per deciliter (ng/dL)
  • Castration-resistant prostate cancer documented by time to prostate-specific antigen (PSA) increase during continuous treatment with androgen deprivation therapy (ADT) OR radiographic progression of soft tissues OR radiographic progression of bone according to PCWG3

Exclusion criteria

Exclusion Criteria:

  • Predominately small cell or neuroendocrine carcinoma of the prostate
  • Known (even if treated) or untreated epidural spread
  • Prior chemotherapy for prostate cancer, except if administered in the /neoadjuvant setting, or up to 6 cycles of docetaxel for hormone-sensitive prostate cancer
  • Treatment with medications known to lower the seizure threshold or any agent that were not discontinued or substituted greater than or equal to (>=)28 days prior to randomization
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    JNJ-809 plus Apalutamide (Group A)

    JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.

    Drug: JNJ-809 · Drug: Apalutamide

  • Experimental
    Apalutamide (Group B)

    Apalutamide 240 mg orally daily.

    Drug: Apalutamide

Interventions

  • DrugJNJ-809

    JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.

  • Apalutamide 240 mg orally daily.

06

What researchers measure

Primary outcomes

  1. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression will be measured using Prostate Cancer Working Group 3 (PCWG3).

    Time frame: approximately 2 years

Secondary outcomes

  1. PSA Doubling Time (PSADT)

    The PSADT will be determined using the method as recommended by PCWG3 criteria.

    Time frame: approximately 2 years

  2. Radiographic Progression-free Survival

    Radiographic progression-free survival, is defined as the time from the date of randomization to the date of radiographic progression or death, whichever occurs first.

    Time frame: approximately 2 years

  3. Time to Unequivocal Clinical Progression

    Time to unequivocal clinical progression defined as the time from the date of randomization to the date of unequivocal clinical progression as evaluated by the investigator.

    Time frame: approximately 2 years

  4. Overall Survival

    Overall survival defined as time from the date of randomization to death from any cause.

    Time frame: approximately 2 years

  5. Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

    Comparison of the AE profiles of the two treatment groups.

    Time frame: approximately 2 years

  6. Blood Culture and Shedding Profile of JNJ-809 From Cultured Samples of Feces, Urine, and Saliva

    Blood culture samples will be collected after the mandatory prophylactic antibiotic therapy. Bacterial shedding will be evaluated from cultured samples of feces by stool or rectal swab, urine, and sputum.

    Time frame: approximately 2 years

07

Study locations

1 site
  • New York, New York, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Sep 2018 and a completion of Sep 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2016
First posted
Sep 20, 2016
Start
Oct 2016
Primary completionEst.
Sep 2018
CompletionEst.
Sep 2018
Last update
Nov 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02906605
Responsible party
Sponsor
First posted
Sep 20, 2016
Start date
Oct 2016
Primary completion
Sep 2018 (estimated)
Completion
Sep 2018 (estimated)
Last update
Nov 22, 2016

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion